Anthera Pharmaceuticals Competitors

VG Life Sciences (OTCMKTS:VGLS) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Volatility and Risk

VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares VG Life Sciences and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares VG Life Sciences and Anthera Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings for VG Life Sciences and Anthera Pharmaceuticals, as reported by MarketBeat.

Summary

Anthera Pharmaceuticals beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Anthera Pharmaceuticals' revenue, earnings per share and valuation.

Anthera Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and target prices for Innovus Pharmaceuticals and Anthera Pharmaceuticals, as provided by MarketBeat.com.

Volatility and Risk

Innovus Pharmaceuticals has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Innovus Pharmaceuticals and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 16.4% of Innovus Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Innovus Pharmaceuticals beats Anthera Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Anthera Pharmaceuticals and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Volatility and Risk

Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Anthera Pharmaceuticals and Immune Pharmaceuticals, as reported by MarketBeat.

Profitability

This table compares Anthera Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Anthera Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Capstone Therapeutics and Anthera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Anthera Pharmaceuticals has lower revenue, but higher earnings than Capstone Therapeutics.

Risk and Volatility

Capstone Therapeutics has a beta of 176.15, indicating that its share price is 17,515% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares Capstone Therapeutics and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Capstone Therapeutics and Anthera Pharmaceuticals, as provided by MarketBeat.

Summary

Capstone Therapeutics beats Anthera Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Anthera Pharmaceuticals (OTCMKTS:ANTH) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Anthera Pharmaceuticals and RespireRx Pharmaceuticals, as provided by MarketBeat.com.

Earnings & Valuation

This table compares Anthera Pharmaceuticals and RespireRx Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Volatility and Risk

Anthera Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Anthera Pharmaceuticals and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Anthera Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional and Insider Ownership

7.3% of VIVUS shares are held by institutional investors. 12.0% of VIVUS shares are held by company insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for VIVUS and Anthera Pharmaceuticals, as reported by MarketBeat.com.

Valuation & Earnings

This table compares VIVUS and Anthera Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Anthera Pharmaceuticals has lower revenue, but higher earnings than VIVUS.

Volatility and Risk

VIVUS has a beta of -3.25, indicating that its stock price is 425% less volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares VIVUS and Anthera Pharmaceuticals' net margins, return on equity and return on assets.